Decision to issue KRW 7 billion premium convertible bonds (conversion price KRW 18,659, +12% vs market)

Decision to issue 7 billion won in unregistered, unsecured private convertible bonds (16th series) with 0% coupon, 2% YTM, maturity June 1, 2031
Conversion price set at 18,659 won, a 12% premium over the closing price of 16,660 won on the subscription date; conversion would result in 375,154 new shares (0.84% dilution of total outstanding)
All proceeds planned for R&D expenses in clinical trials for progressive supranuclear palsy (PSP) and other indications
Total potential dilution including previously issued CBs and BWBs stands at 5.03%